Can New Biomarker Help Identify High-Risk DLBCL Patients?

Minimal residual disease-negativity after treatment in DLBCL strongly correlates with remission and overall survival. However, clinical trials are needed to clarify the optimal clinical utility.
Medscape Medical News

source https://www.medscape.com/viewarticle/can-new-biomarker-help-identify-high-risk-dlbcl-patients-2025a1000eqy?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost